SARS-CoV-2 vaccines in development
2020/09/23 by Florian Krammer · 2 citations
Mathematics · Medicine · #COVID-19 Clinical Research Studies #COVID-19 epidemiological studies #SARS-CoV-2 and COVID-19 Research
paper · doi:10.1038/s41586-020-2798-3
crossref issued 2020/09/23 · crossref published 2020/09/23 · crossref published-online 2020/09/23 · openalex publication_date 2020/09/23 · crossref created 2020/09/23 · crossref published-print 2020/10/22 · crossref deposited 2022/11/19 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01 · crossref indexed 2026/08/05
Citations
- Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Cited by